Herzuma’s Biosimilar Herzuma Finds EC Approval

The European Commission approved Celltrion’s Herzuma used in the treatment of early and metastatic breast cancer, following a positive opinion from the Committee for Medicinal Products for Human Use.

Herzuma (trastuzumab biosimilar), an anticancer monoclonal antibody biosimilar that is also used to treat gastric cancer, was approved for the treatment of patients whose tumors have either experienced HER2 overexpression or HER2 gene amplification. It marks the third Herzuma biosimilar approval by the EC.

“Our experience has shown that biosimilars not only reduce individual patient’s out-of-pocket medical expenses but also contribute to lowering financial burden on insurance payers and national health agencies,” said Celltrion’s CEO Woosung Kee.